52
Participants
Start Date
September 9, 2020
Primary Completion Date
December 29, 2023
Study Completion Date
March 29, 2026
Camrelizumab
Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
Oxaliplatin
Oxaliplatin: 130 mg/m\^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks. Repeated every 21 days, 21 days for a cycle.
Tegafur gimeracil oteracil potassium capsule
Tegafur gimeracil oteracil potassium capsule: 80 mg/m\^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Repeated every 21 days. 21 days for a cycle.
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou
Taizhou Hospital, Taizhou
Lishui Central Hospital, Lishui
The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou
Yu jiren
OTHER